pirodavir has been researched along with Enterovirus Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelnabi, R; Camarasa, MJ; Fernández-Barahona, I; Gago, F; Herranz, F; Martí-Marí, O; Martínez-Gualda, B; Mills, A; Neyts, J; Noppen, S; San-Félix, A; Schols, D | 1 |
| Franco, D; Froeyen, M; Hilgenfeld, R; Leyssen, P; Neyts, J; Tijsma, A; Tucker, S | 1 |
2 other study(ies) available for pirodavir and Enterovirus Infections
| Article | Year |
|---|---|
Organotropic dendrons with high potency as HIV-1, HIV-2 and EV-A71 cell entry inhibitors.
Topics: Dendrimers; Enterovirus A, Human; Enterovirus Infections; HIV Fusion Inhibitors; HIV-1; HIV-2; Humans; Virus Internalization | 2022 |
The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication.
Topics: Antiviral Agents; Benzimidazoles; Capsid; Capsid Proteins; Drug Resistance, Viral; Enterovirus A, Human; Enterovirus Infections; Isoxazoles; Molecular Docking Simulation; Oximes; Phenylalanine; Piperidines; Protease Inhibitors; Protein Binding; Pyridazines; Pyrrolidinones; Sulfonamides; Valine; Virus Replication | 2014 |